Chugai Gets Third US Breakthrough Status, For Hemophilia Antibody
This article was originally published in PharmAsia News
Executive Summary
The US FDA has designated Chugai’s ACE910 as a breakthrough therapy for hemophilia A, making the bispecific antibody the first hemophilia treatment to receive the expedited review status, and marking the third project from the Japanese firm to receive the classification.